04 July 2023
04 July 2023
Data from the phase II trial shows an 84% reduction in generalised pustular psoriasis flare-ups over 48 weeks compared to placebo.
Measuring weekly episodes of cataplexy over eight weeks is the trial's primary endpoint.
Following positive data results, Nicox continues to investigate NCX 470 in ongoing and planned Phase III trials.
Patients who underwent renal denervation demonstrated a greater blood pressure reduction than the sham group.
Complete improvement in skin clearance was observed at the highest dose level tested against placebo after 16 weeks.
CAN008 is a CD95-Fc fusion protein that inhibits T-cell apoptosis and the invasive growth and migration of tumour cells.
The findings show that the treatment might benefit those experiencing migraine.
Participants who received 0.6 mg and 1.2 mg ZP8396 showed mean body weight reductions of 5.3% and 5.1%, respectively.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
